HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Poseida Therapeutics (NASDAQ:PSTX) and maintained a $20 price target.
May 22, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Poseida Therapeutics and maintained a $20 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $20 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100